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ABSTRACT
During the STS-50/USML-1 mission and 5 other Shuttle flights, decompression of the legs
and lower abdomen ("lower body negative pressure," LBNP) was used (1) to apply a standardized
stress to the cardiovascular system, to document the loss of orthostatic function during an
extended period in weightlessness, and (2) to test its efficacy as a treatment which may be used to
protect astronauts from gravitationally-induced fainting during and after reentry on Space Shuttle
flights.
The loss of orthostatic tolerance (as determined by LBNP) occurred even earlier than
indicated by similar testing on Skylab (1973-1974). The treatment was shown to be effective in
reversing some of the effects of extended weightlessness on the cardiovascular system for at least
one day after treatment.
NOMENCLATURE
ABPM
AERIS
BP
Bradycardia
CO
Diastolic
Dysrhythmia
Automatic Blood Pressure Monitor
"American Echocardiograph Research Imaging System',
a modified commercial cardiac ultrasound device
Blood pressure, the result of the ejection of blood
from the heart into the elastic arteries, especially the aorta
Slow heart rate
Cardiac output, the volume of blood ejected during one minute
During the relaxation phase of the heart beat
Abnormal heart beat
Joint "L+I" Science Review for USML-1 and USMP-I ufith the Microgravity Measurement Group, September
22-24, 1993, Huntsuille, Alabama, USA.
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ECG
JSC
LBNP
MSFC
Orthostatic
Plethysmograph
SV
Systolic
Tachycardia
TPR
Electrocardiogram, also known as EKG
Johnson Space Center, Houston, Texas
"Lower body negative pressure", the decompression
of the legs and lower abdomen to allow blood pooling
mimicking that in the upright posture
Marshall Space Flight Center, Huntsville, Alabama
Relating to the upright posture on Earth's surface
A device for measuring the volume of a limb
Left ventricular stroke volume, the volume of
blood ejected with each heart beat
During the contraction phase of the heart beat
Rapid heart rate
Total peripheral resistance, the result of the
constriction of the small arteries throughout the circulatory system
INTRODUCTION
A candidate countermeasure against orthostatic intolerance after space flight was evaluated
for its efficacy and operational practicality. This countermeasure, lower body negative pressure
(LBNP) combined with salt, and fluid ingestion, is intended as a single-application, end-of-mission
treatment to pre-adapt the cardiovascular system to exposure to orthostatic stress during and after
Space Shuttle reentry, landing and cabin egress. The countermeasure evaluation involved 12 crew
members as in-flight participants on six Shuttle flights of 9-14 days duration.
Exposure to weightlessness, even for short periods, induces significant changes in the
cardiovascular system which are proposed to be secondary to headward fluid shifts, subsequent
plasma volume contraction, and ensuing adaptations in cardioregulatorory function (1). The resulting
cardiovascular state is inappropriate for orthostasis on Earth as manifested by the clinical findings of
tachycardia, decreased exercise capacity and orthostatic intolerance (demonstrated by symptoms of
dizziness) and presyncope or syncope (loss of consciousness) on return to Earth.
These findings prompted operational concerns for Space Shuttle crew members, due to their
upright posture during Shuttle reentry and landing maneuvers and to the high degree of pilot
involvement in the Shuttle landing process (2). These concerns have become especially pertinent as
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Shuttle flight durations are extended, presumably predisposing the astronauts to an even greater
risk of orthostatic intolerance during this critical mission phase (2).
Development of appropriate countermeasures to this cardiovascular change has been a
priority of NASA's in-house directed medical research. One candidate countermeasure under
investigation since the 1960s (6) involves lower body decompression (LBNP). This technique, which
typically decompresses the legs and abdomen by up to 50 mm Hg, provides a cardiovascular stress
similar to standing upright (orthostasis) by allowing blood to pool in the legs and abdomen (14).
Brief decompression is used as a gravity-independent test of orthostatic capacity; longer
decompression, either alone or in combination with salt and water ingestion, has been used as a
countermeasure to restore orthostatic tolerance in bedrested subjects and astronauts. LBNP has
been used in both of these capacities during Russian and U.S. manned space flights.
The first in-flight assessment of orthostatic tolerance was performed on the Soviet Union's
Salyut 1 space station in 1971 (4). Two of the three crewmen were tested once in flight, on day
13 of their 24-day flight, using a prototype of the now-standard "Chibis" pneumatic vacuum suit.
Two years later, the Skylab program allowed U.S. investigators to determine the time course of the
development of orthostatic dysfunction in weightlessness (11, 12, 13). During all three Skylab
missions (28, 59, and 84-day durations), crew members' heart rate (HR) and blood pressure (BP)
responses to the standardized graded stress provided by the onboard LBNP device were recorded at
approximately 3-4 day intervals. During the initial in-flight tests, which were performed on the 4th,
5th, and 6th days of flight, HR responses to the stress were already exaggerated compared to
preflight tests. Resting HR plateaued after about 10 days of weightlessness; stressed HR plateaued
after 20 days of weightlessness. BP was generally maintained throughout those LBNP studies that
did not end in presyncope or bradycardia. The greater increase in HR during flight than before flight
could reflect compensation for a reduction in blood volume early in flight. Calf volume increases
with LBNP were greater during flight than before flight, probably because greater volumes of blood
were required to fill the relatively empty leg veins during flight.
LBNP testing of cardiovascular function has been performed during all but one of the
missions to the Russian Salyut and Mir space stations. In agreement with the U.S. Skylab data,
testing of the crews of the 49-day and 17-day missions to Sal_/ut 5 indicated that individual
responses to in-flight LBNP tests were predictive of postflight responses to orthostatic stress (5).
The development of LBNP-based countermeasures proceeded independently in Russia and
the U.S. Soviet researchers developed an LBNP countermeasure for use on long duration space
missions (7). Since the mid-1970s, a routine multi-week course of LBNP treatments has gradually
been developed for use by the crews of the Salyut and Mir space stations in preparation for landing.
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Thisnow typicallyincludesbrief,step-wisedecompressionsover20-30 minutesat 4 day intervals
beginning3-4weeksbeforelanding,andculminateswith 1-hoursessionsof gradeddecompressions
on thelast two full daysin flight. Extrasalt is takenwith mealsonthosedays.
In the U. S.,a varietyof LBNPprotocolsweredevelopedwhichwereeffective in preventing
or reversing orthostatic intolerance during bedrest but which were also prohibitively long (several
days) at the end of the bedrest (6). The breakthrough came in 1977 when Hyatt and West (9)
demonstrated that a single application of only 4 hours of LBNP, when combined with the ingestion
of one liter of a bouillon solution, restored plasma volume and orthostatic tolerance to pre-bedrest
levels for at least 18 hours, even after seven days of bedrest. This result was confirmed in six
subjects after two weeks of bedrest (10). The effective treatment period could not be reduced
below 4 hours using the same protocol (one liter of isotonic solution and 30 mm Hg
decompression).
These investigations formed the basis for the combined treatment countermeasure for
orthostatic intolerance that has been tested during Shuttle flights.
I. METHODS
A collapsible LBNP device developed for use on-board the Space Shuttle was used for all in-
flight decompressions (Figure (1)). A modified ambulatory blood pressure monitor measured HR and
BP and provided analog electrocardiogram and BP signals for telemetry to MSFC and JSC. Cardiac
ultrasound measurements of left ventricular end-diastolic volume) were performed in-flight on 4
Shuttle flights (STS-32, 43, 47, and 50). Ultrasound Doppler measurements of aortic blood flow
(for calculation of stroke volume, cardiac output and total peripheral resistance) were performed for
the first time in-flight on STS-50 (USML-1) using the AERIS device. In-flight leg volume
measurements using the stocking plethysmograph were performed on STS-47 and STS-50 only.
On the USML-1 mission, LBNP was performed in-flight as tests ('ramps") of cardiovascular
response, a treatment ('soak') and follow-up ramp tests to determine the effectiveness of the
treatment after 24-hours and 48-hours. This time frame was selected to simulate a nominal
landing 24-hours after the soak and a 1- day delay in landing (48-hours after the soak). The in-
flight ramp and soak protocol are outlined in Figures (2) and (3) respectively.
The ramp tests consisted of 10 minutes of baseline data collection at 0 mm Hg of /BNP
device decompression, 5 minutes of data collection at each step of decompression (10, 20, 30, 40
and 50 mm Hg), and 5 minutes of recovery data collection after recompression to ambient pressure.
The soak treatment began with a step-wise decompression to 50 mm Hg followed by about 3.5
hours of LBNP at 30 mm Hg below ambient pressure. The total time of decompression of at least
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30 mm Hg was 4 hours. One liter of water or artificially sweetened fruit drink and 8 grams of salt
(NaCI in 1 gram tablets) were ingested during the first hour at 30 mm Hg decompression. The
treatment was evaluated by comparing HR and BP responses to test decompressions on days before
and after treatment.
Test termination criteria for LBNP testing included: achieving a HR equal to the maximum HR
seen in preflight LBNP testing; one-minute decreases in HR of 15 beats/minute, in systolic BP of 25
mm Hg, and /or in diastolic BP of 15 mm Hg; a variety of clinically significant cardiac dysrhythmias;
loss of signal at levels of decompression greater than 30 mm Hg,; and subject request at any time.
Some tests were terminated on STS-50 for the maximum HR criterion; this represented a normal
physiological response to space flight, and did not imply an increased risk to any subject.
I1. RESULTS
The typical HR and BP response to LBNP is shown in Figure 4. Twenty four hours after the
combined countermeasure of salt and water ingestion during LBNP at 30 mm Hg below ambient
pressure, the HR response to 40-50 mm Hg lower body decompression was not statistically
different from the preflight value. However, two days after the combined countermeasure, the HR
response to decompression was not statistically different from the last pre-treatment ramp test.
Thus, the cardiovascular effect of the soak treatment was present in crew members for at least one
day after treatment.
Neither systolic nor diastolic BP responded significantly to the submaximal levels of LBNP
tested in-flight.
Leg volume showed no greater increase after the 4-hour soak than after the 25-minute ramp
tests.
Cardiac ultrasound measurements documented the expected decrease in left ventricular end-
diastolic volume and stroke volume at rest and under LBNP stress. Cardiac output was maintained
by an increase in HR. BP was maintained at preflight levels throughout in-flight testing by an
appropriate increase in total peripheral resistance. Measurements of SV, CO and TPR responses to
the soak treatment were not possible after the AERIS failed on flight day 9.
II1. DISCUSSION
The loss of orthostatic tolerance (as reflected by heart rate response to 40-50 mm Hg
decompression) occurs even earlier in flight than indicated by the Skylab data. The cardiovascular
adaptations to weightlessness are thus shown to be rapid, implying that even short Shuttle flights
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invoke nearly the full cardiovascular risk of orthostatic intolerance heretofore expected only on long
flights.
The candidate treatment has been shown to be effective in restoring HR response to LBNP
stress to its preflight value for at least one day after treatment, but not for two days. Thus, any
operational application of this treatment must be planned for the day before landing; last-minute
delays in landing, such as occurred on STS-50, will require re-treatment for maximum crewmember
safety.
The capability for simulating the effects of orthostatic stress on the cardiovascular system
during Space Shuttle flights has been developed and demonstrated. This capability can be used for
basic and applied research as well as for the application of countermeasures.
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Discussion
Questions: What causes the blood volume loss you talked about ?
Answers: The blood volume loss is believed to be caused by the fact that the normal hydrostatic
pressure gradient which I am feeling at this moment disappears in 0 g. The blood volume which is
normally sequestered in the legs or at least pools in the veins in the legs, then has no reason to pool in
the veins in the legs. Those normal physiological mechanisms that squeeze it back up, act unopposed,
squeezing the blood back up to the thorax and the upper part of the body, the head. In fact, if you look at
photographs of the astronauts in flight, you see sometimes fairly puffy faces and some of the neck veins
and head veins stand out. You will also see what some people call the bird legs of space flight which is
when the legs on the flight get very small. Those mechanisms act unopposed and squeeze the fluid to
the upper part of the body and it just so happens the reflexes which control blood volume are in the
upper part of the body. So as far as the sensors that are built in the cardiovascular system are
concerned, it is not fluid volume shifted, it is too much fluid volume and so they act through a complex
series of mechanisms to reduce the blood volume in the body to an appropriate state. I should stress that
all the data we have indicates the appropriate adaptation of normal, healthy people to space flight, and
this is fine as long as they stay in space flight. If they are brash, as in to try to land and come to l-g,
then it is not an appropriate adaptation to life at 1-g post flight.
Question: So the ratio of the red cells to water in the blood goes up ?
Answer: It goes up briefly in flight, by briefly I mean a few weeks. As you excrete the watery portion of
the blood you leave behind the red cells and the fraction increases and so the ratio increases. The body
seems to have sensors for this as well, and seems to decrease the production of red cells to bring the
ratio back down to normal. That is the adaptation, that is the anemia that you will sometimes hear about
in space flight.
Question: If the baro receptors are being fooled because you have a shift, because you have a shift in
your fluid, why is it that the longer you stay in space the thought is, the worse off you will be in terms of
this hypertension effect ?.
Answer: Well in fact, we physiologists and medical researchers have made some fairly naive
assumptions about the effect of prolonged space flight. My current thinking is the stress in the
cardiovascular system changes faidy quickly in orbit, within hours to days within reaching orbit. I think
the cardiovascular stresses, especially the change stimulation of the bare receptors in the body occurs
quickly in flight, and probably doesn't increase too much beyond the first few days to weeks in flight. II
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think the evidence from Skylab, the Shuttle, the Salyut and Mir flights, all experiments from pre and post
flight show that the effect of a 4 or 5 day flight probably is not going to differ dramatically from a 14 day
flight. What that means and it sounds good, it sounds like we are flying 4 and 5 day flights routinely with
no problem so there is no problem flying longer missions, but I am here to tell you that is not the case.
We have problems out there with shorter flights that need to be paid attention to.
Question: Is it possible that as they sit in an environment where there is not much fluctuation, they
somehow lose the ability to monitor the situation and so when you return to Earth, they don_ work as
well?
Answer: That is our hypothesis. That was the hypothesis of the experiment that was done on the blue
shift with the blood pressure variability. I still believe in the hypothesis, I just don_ think we have the
right technology to demonstrate that.
Question: There are other counter measures, some we used on our flight (USML-1). Has there now
been enough data accumulated to start to compare them and see which one is more effective ?
Answer: The other counter measures that were used on your flight included an intense bout of exercise.
I believe one or two people on your crew did it the day before landing, the idea there being, to follow up
on bed rest study which may show that an intense bout of maximal exercise has the effect of restoring
the plasma volume as we discussed here a few moments ago, and thereby hopefully increasing other
static tolerance. Another counter measure was the application of a synthetic version of a normally
occurring hormone. The hormone is called aldosterone which forces the body to retain salt and thereby
retain water. That was used in a couple of individuals as well. Both of these investigations have occurred
on other flights and the results are equivocal from those investigations. I do not have a high level of
confidence in the hormone as an effective counter measure based on the data we have. Because they
are attractive in terms of taking a pill versus 4 hours of LBNP, we continue to investigate, making sure
we are making the fight measurements in bed rest and in space flight, to demonstrate that it does or
does not work effectively.
Question: Could you comment on the amount of variability in cardio-vascular changes among different
crew members in flight ?
Answer: There is a depressing amount of variation among individuals. There are some people who fly
10 and 14 day missions, who are immune, who have no difficulty at all and there are some folks that fly 4
day missions who are in fairly sorry states after landing. 1can qualify that with two episodes. One of the
treatments for orthostatic intolerance and for a general physiological depressed state is to reinfuse some
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fluid volumes. You have all seen the bags of saline that physicians will put through a vein and restore
some blood volume. That has occurred on two incidences that I know of on shuttle flights. One after a
10 day flight and one after a four day flight. Based on just that little evidence alone, there is not an
appreciable agreement in the cardiovascular or the static effects of 4 to 10 day flights and, like I say, it is
not good news for the long flights, but it is bad news for the short flights.
Question: Is there any correlation between the amount of changes in an individual and the tendency to
sea sickness ?
Answer: Well by the term sea sickness we relate that to space motion sickness and I don_tthink there is
a good correlation. I am told there is not a good correlation between any kind of motion sickness on the
ground and motion sickness in flight, but there is no doubt that there is motion sickness. And there is an
incidence, depending on how you quantify it, of 25-50% plus of motion sickness in flight. We have shown
that the folks that have the most trouble standing up post flight are also the folks that were the sickest on
flight. There was a strong correlation between being sick in flight and having this apparently unrelated
cardiovascular problem on landing day. Now what that tells me is two things. If you are sick in flight,
either you are not eating or drinking and keeping yourself well hydrated and well nourished and you are
putting yourself at physiological risk or maybe it is folks that are sick in flight are doomed to be sick in
flight and are doomed to have cardiovascular problems post flight because a lot of the reflexes are
common in both syndromes. We cannot differentiate between those, but we do encourage crew
members to eat, hydrate and nourish themselves properly and to get as much rest as we, the
investigators, will allow them to have. I have to wear two different hats because as a physiologist who is
doing research, I have to say rest is for the wimps and lets get on with some more LBNP studies, but as
someone who is charged with providing the astronauts well being there is no doubt that properly eating
and resting are vital to continued safe function and flight.
Question: How do you choose the pressure levels selected during LBNP and are you likely to change
them ?
Answer: I am not likely to change them. We have modified them a little bit. The pressure levels that
you are thinking of 0, 10, 20, 30, 40, 50 mm-mercury decompressions are based actually on a long
history of LBNP work preceding in fact Skylab. The investigators that did the work on Skylab established
the -50 millimeters mercury as being a physiological analog to standing upright. So it seemed like a
logical thing to investigate, if you are interested in the ability of astronauts to stand upright post-flight. It
has become enshrined in literature. So if I want to maintain comparability between Skylab data and my
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data in the literature base, I need to maintain comparability to those levels of decompression. But briefly
-50 roughly approximates standing upright at 1-g.
Question: Could you comment on the soaking parameters.
Answer: The soaking is done with the -30 mm of mercury pressure because nobody wants to stand
upright for 4 hours or longer. It was decided to pick a level that was tolerable for 4 hours but still a
significant stress to exercise the cardiovascular system.
Question: Is there any reason that we can? do the soaks during crew sleep period ?
Answer: That is an excellent question. At first brush I am reluctant to do that because part of our
monitoring of crew assurance and crew health is that the crew members don't faint during LBNP crew
testing. And if someone is asleep you can_ tell if they have fainted or not because they are unconscious.
That would possibly eliminate a first line of protection in a very conservative medical monitoring
situation. However, if we choose the appropriate level of LBNP, for example, say 15 millimeters of
mercury for 8 hours instead of 30 millimeters of mercury for 4 hours, we might be able to circumvent with
the appropriate medical monitoring equipment for heart rate and blood pressure that I showed you on the
first view graph, there may be ways to go around that. I am not saying that 15 mm x 8 hours is
equivalent to 30 mm x 4 hours. The only treatment that has been tried and is effective is 30 mm for 4
hours. A lot of investigators spent a lot of time back in the 60's and 70's looking at other combinations
and that was the one that worked, really worked, with the addition of salt and water. So one of the tasks
as we move in to the Space Station era and as we move further into the Space Shuttle era, is to try to
optimize these kind of measures. If we can optimize it, by applying it during the sleep period, we will do
so enthusiastically, but that has not been shown yet.
Question: Are the baro receptors localized or distributed in the body ?
Answer: The baro receptors are essentially nerve endings which wrap around the blood vessels. So if
this is my artery, the baro receptors sort of wrap around and as your artery expands each time your heart
beats those receptors stretch and with the influx of sodium across the membrane trigger additional
activity along that nerve's fibers that is interpreted at the brain as whatever is supposed to be occurring
at that location. The baro receptors are located preferentially in the carotid sinuses and the aortic arch.
The aorta is the large artery that comes off the heart and carries blood throughout the body. In the arch
of the aorta there are some baro receptors. Those are the two major areas of baro receptors. Baro
meaning pressure, receptors meaning receptors or sensors. Those are the two areas that we are
interested in the cardiovascular business. Now how those signals change at the sensor level, how the
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mediation of those signals back to the brain and the brain stem changes and how the activity from the
brain affects the effective organ changes, those questions all remain to be answered in space flight.
They are going to be fairly invasive and faidy complex questions to answer, so we are trying to move in
the other direction by applying essentially a black box as a cure to a very complex problem and sort of a
stop gap solution to a problem.
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